The Boeing Company
$205.04B- Market cap
- $161.87B
- Debt
- +$54.10B
- Cash
- −$10.92B
Capital structure 75% equity / 25% debt · EV / Revenue 2.29x · EV proxy / EBITDA proxy 32.89x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $161.87B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: BA stock price vs PACB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PACB's multiple
Needs PACB P/E.
Implied fair value · at BA's multiple
Needs Annual EPS is negative.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 75% equity / 25% debt · EV / Revenue 2.29x · EV proxy / EBITDA proxy 32.89x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
THE BOEING COMPANY · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Pacific Biosciences of California, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BA can sustain positive earnings and revenue growth without a material deterioration in leverage or distress metrics, then BA looks attractive relative to PACB because BA combines a lower P/S multiple with far stronger profitability and returns.
BA’s current price of $216.14 is below the implied price of $309.59, indicating 43.2% upside on the stated P/S basis. The valuation gap is reinforced by BA’s lower P/S multiple than PACB and by BA’s position within its historical trading band.
Supporting Metrics